Neoadjuvant Radiotherapy Shows Survival Benefit in Locally Advanced Rectal Cancer Despite Increased Stoma Risk
Key Insights
Neoadjuvant radiotherapy followed by surgery improved 3-year overall survival to 88.5% compared to 85.2% with upfront surgery in locally advanced rectal cancer (search) patients.
The treatment approach significantly increased pathologic complete response rates (22.4% vs 9.2%) and tumor downstaging compared to chemotherapy alone.
Radiotherapy was associated with higher rates of diverting stoma creation (65.5% vs 41.0%) and permanent stomas (20.6% vs 11.1%).
A comprehensive analysis of neoadjuvant treatment strategies for locally advanced rectal cancer (search) reveals that radiotherapy provides significant survival benefits but comes with increased complications, particularly regarding stoma creation and reversal rates.
Survival Outcomes Favor Radiotherapy Approach
A Taiwanese nationwide registry study of 3,792 patients demonstrated that neoadjuvant radiotherapy followed by surgery achieved a 3-year overall survival rate of 88.5% compared to 85.2% with upfront surgery (HR, 0.74; 95% CI, 0.59-0.92). The survival advantage was accompanied by comparable local recurrence rates of 5.7% versus 6.6%, respectively, which was not statistically significant (HR, 0.78; 95% CI, 0.55-1.11).
"In this cohort study of nationwide registries in Taiwan, neoadjuvant radiotherapy prior to surgery was associated with improved outcomes for patients with resectable locally advanced rectal cancer (search) overall compared with up-front surgery," wrote lead study author Po-Chuan Chen, MD, of National Cheng Kung University Hospital.
Enhanced Pathologic Response with Radiotherapy
A separate Chinese study of 380 patients comparing neoadjuvant chemoradiotherapy (nCRT) with chemotherapy alone (nCT) revealed striking differences in pathologic outcomes. The nCRT group achieved a pathologic complete response rate of 22.4% versus 9.2% in the nCT group. Tumor downstaging occurred in 69.4% of nCRT patients compared to 47.8% of nCT patients, while favorable tumor regression grades (TRG 1-2) were observed in 59.7% versus 24.5%, respectively.
Multivariable analysis demonstrated that nCRT patients had more than double the pathologic complete response rate (HR 2.941, 95% CI 1.594-5.429, P < 0.001) compared to chemotherapy alone.
Stoma Complications Present Significant Trade-off
The Taiwanese study revealed that approximately half of all surgical patients (49.4%) underwent diverting stoma creation, but rates varied dramatically by treatment approach. Patients receiving neoadjuvant radiotherapy had significantly higher rates of diverting stoma creation at 65.5% compared to 41.0% for upfront surgery (risk ratio, 1.60; 95% CI, 1.46-1.75).
More concerning, permanent diverting stomas occurred in 20.6% of radiotherapy patients versus 11.1% of upfront surgery patients (risk ratio, 1.91; 95% CI, 1.62-2.25). While 71.6% of stomas were closed within one year, 26.6% remained unreversed at three years, with 13.1% of all patients having permanent diverting stomas.
Tumor Location Influences Treatment Benefits
Subgroup analysis based on tumor height revealed important distinctions in radiotherapy effectiveness. For lower rectal cancers, neoadjuvant radiotherapy was associated with significantly increased overall survival (HR, 0.66; 95% CI, 0.46-0.96) and reduced local recurrence (HR, 0.53; 95% CI, 0.30-0.95). However, upper rectal cancers showed no improvement in overall survival (HR, 1.54; 95% CI, 0.82-2.90) or local recurrence (HR, 1.08; 95% CI, 0.23-5.00).
The Chinese study corroborated these findings, showing that for tumors located ≥8 cm from the anal verge, outcomes were comparable between radiotherapy and chemotherapy approaches, except for higher preventive stoma rates in the radiotherapy group.
Risk Stratification Guides Treatment Selection
Analysis by European Society of Medical Oncology risk categories demonstrated that bad-risk patients particularly benefited from neoadjuvant radiotherapy. The nCRT group showed superior 3-year locoregional relapse-free survival (98.1% vs 88.0%, P = 0.031) in bad-risk patients compared to chemotherapy alone.
"Patients with bad-risk or tumors located at <8 cm from the anal verge may be benefited from nCRT," the researchers concluded, suggesting that tumor location and risk category could serve as practical indices for clinical decision-making.
Safety Profile and Complications
The radiotherapy approach was associated with increased toxicity profiles. Grade 1-2 adverse events were more common with nCRT, including myelosuppression (69.9% vs 37.0%), diarrhea (54.1% vs 10.3%), and postoperative complications such as bowel obstruction (9.2% vs 1.1%) and anastomotic stenosis (4.1% vs 0.5%).
Radiation-specific toxicities included proctitis in 32.1% of patients and dermatitis in 24.5%. Despite these complications, treatment adherence remained high, with no patients interrupting pelvic radiotherapy and 90% undergoing successful stoma reversal.
Clinical Implications for Treatment Selection
The research suggests a nuanced approach to neoadjuvant therapy selection. Chen and colleagues noted that "for upper rectal cancer (search), the trade-off between using neoadjuvant radiotherapy to pursue better oncological outcomes and creating diverting stomas to lower the risk of symptomatic leak may not be justified."
The findings support current trends toward total neoadjuvant therapy for high-risk patients while questioning the routine use of radiotherapy for upper rectal tumors in intermediate-risk categories. The data indicate that tumor location ≥8 cm from the anal verge combined with intermediate risk factors may justify omitting radiotherapy in favor of chemotherapy alone.
These real-world analyses provide crucial evidence for personalizing neoadjuvant treatment strategies in locally advanced rectal cancer (search), balancing oncologic outcomes against quality of life considerations in an era of evolving treatment paradigms.